These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22564133)

  • 1. Bevacizumab in ovarian cancer: unanswered questions.
    Muggia F
    Drugs; 2012 May; 72(7):931-6. PubMed ID: 22564133
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Dhillon S
    Drugs; 2012 May; 72(7):917-30. PubMed ID: 22515620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
    Nimeiri HS; Oza AM; Morgan RJ; Friberg G; Kasza K; Faoro L; Salgia R; Stadler WM; Vokes EE; Fleming GF; ; ;
    Gynecol Oncol; 2008 Jul; 110(1):49-55. PubMed ID: 18423560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.
    Dao MD; Alwan LM; Gray HJ; Tamimi HK; Goff BA; Liao JB
    Gynecol Oncol; 2013 Aug; 130(2):295-9. PubMed ID: 23632207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
    Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
    Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
    J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on "Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery".
    Barton DP; Naik R; Pomel C
    Int J Gynecol Cancer; 2012 Sep; 22(7):1104-5. PubMed ID: 22914211
    [No Abstract]   [Full Text] [Related]  

  • 10. VEGF inhibitors and advanced ovarian cancer.
    Jayson G
    Lancet Oncol; 2011 Nov; 12(12):1082-3. PubMed ID: 21992854
    [No Abstract]   [Full Text] [Related]  

  • 11. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
    J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP; Goldstein BH; Rettenmaier MA; Genesen M; Graham C; Bader K; Lopez KL; Nickle M; Brown JV
    Int J Gynecol Cancer; 2007; 17(4):771-6. PubMed ID: 17343605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view.
    Tomao F; Tomao S; Panici PB
    J Clin Oncol; 2013 Jan; 31(1):166-7. PubMed ID: 23169499
    [No Abstract]   [Full Text] [Related]  

  • 14. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
    Collinson F; Hutchinson M; Craven RA; Cairns DA; Zougman A; Wind TC; Gahir N; Messenger MP; Jackson S; Thompson D; Adusei C; Ledermann JA; Hall G; Jayson GC; Selby PJ; Banks RE
    Clin Cancer Res; 2013 Sep; 19(18):5227-39. PubMed ID: 23935036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.
    Nanki Y; Nomura H; Iwasa N; Saotome K; Dozen A; Yoshihama T; Hirano T; Hashimoto S; Chiyoda T; Yamagami W; Kataoka F; Aoki D
    Jpn J Clin Oncol; 2021 Jan; 51(1):54-59. PubMed ID: 32776094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
    Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab in ovarian cancer.
    Mountzios G; Pentheroudakis G
    N Engl J Med; 2012 Mar; 366(13):1257; author reply 1258. PubMed ID: 22455430
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab in ovarian cancer.
    Copur MS; Obermiller AM; Ramaekers R
    N Engl J Med; 2012 Mar; 366(13):1256-7; author reply 1257-8. PubMed ID: 22455429
    [No Abstract]   [Full Text] [Related]  

  • 19. Bevacizumab in ovarian cancer.
    Korn EL; Freidlin B; Abrams JS
    N Engl J Med; 2012 Mar; 366(13):1256; author reply 1257-8. PubMed ID: 22455428
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
    McGonigle KF; Muntz HG; Vuky J; Paley PJ; Veljovich DS; Greer BE; Goff BA; Gray HJ; Malpass TW
    Cancer; 2011 Aug; 117(16):3731-40. PubMed ID: 21815133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.